Seeking Alpha

KarinCA

 
View as an RSS Feed
View KarinCA's Articles BY TICKER:
  • Ebola Treated With GlaxoSmithKline Subsidiary HIV Product
    Fri, Oct. 3 GSK 14 Comments

    Summary

    • GSK is one of the companies recently thrust into the news due to the current Ebola outbreak.
    • While working on a vaccine against Ebola a Dr in Liberia has started using their HIV drug lamivudine successfully against Ebola.
    • This method is bypassing trials and there are risks. But, it’s approved for human use and ready to go.
  • Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix
    Thu, Sep. 25 OTIC 19 Comments

    Summary

    • Antibiotic resistance is such a significant threat to the achievements of modern medicine that we are now seeing regulatory support for companies developing antibiotics.
    • Growing opportunities are opening up for developmental stage biotechs in the field of antibiotics that haven’t existed in the past.
    • Investors suddenly have more choices and following are some options.
  • Update: Tekmira Pharmaceuticals Corp. Has A Framework To Treat Ebola Patients
    Mon, Sep. 22 TKMR 25 Comments

    Summary

    • The FDA and Health Canada have created a framework and protocol to allow Tekmira to treat confirmed or suspected Ebola cases.
    • The therapy has now been used in patients with Ebola.
    • It was anticipated to happen, but not the timing.
  • Update: Cellceutix Calls Out To President Obama About Brilacidin
    Sun, Sep. 21 CTIX 60 Comments

    Summary

    • On September 19, 2014, CTIX issued a bold press release about a new Executive Order relating to antibiotic resistance.
    • The company expects top line data from the Brilacidin Phase 2b trial to be positive. The entire defensin-mimetic portfolio is expected to be supported by the new Presidential Order.
    • President Obama’s signing of the Executive Order on September 18, 2014 to combat the threat from bacteria resistant to current antibiotic treatment was unexpected. This changes the antibiotic space.
  • Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
    Sun, Sep. 14 CTIX 76 Comments

    Summary

    • Brilacidin highlighted at Rodman & Renshaw and in a press release September 9, 2014.
    • Brilacidin is poised to move the share price before Kevetrin or Prurisol do.
    • At the time of original article, Cellceutix didn't have Brilacidin in the pipeline.
  • 4 Companies To Look At After WHO Ebola Consultation In Geneva
    Mon, Sep. 8 GSK, NLNK, RAI 23 Comments

    Summary

    • The current Ebola outbreak has thrust four companies prominently into the news with their therapies and/or vaccines. Three are publicly traded, and one is privately held.
    • The World Health Organization (WHO) consultation of September 4-5 in Geneva came out with a plan to test some of these experimental vaccines and therapies.
    • The common risks these companies face.
  • Tekmira Pharmaceuticals Is More Than Just A Short-Term Ebola Trade
    Wed, Aug. 27 TKMR 69 Comments

    Summary

    • Ebola has thrust a virtually unknown company into the spotlight. Unknown to average retail investors, but, not unknown in its industry, Tekmira has some interesting technology and partners.
    • The pipeline may turn this into a longer-term hold once the volatility subsides.
    • TKM-Ebola and why it’s currently ahead of the competition.
  • Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets
       • Sep. 18, 2013 CTIX 39 Comments
  • Holloman Energy Corp.: Drilling To Start In Australia's Cooper Basin Any Day Now
    Jul. 16, 2013 HENC 12 Comments
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population
    Jul. 15, 2013 ISCO 74 Comments
  • An Interview With Leo Ehrlich, Cellceutix CEO
    Mar. 14, 2013 CTIX 35 Comments
  • Which Drug Moves Cellceutix First: Kevetrin Or Prurisol?
    Jan. 28, 2013 CTIX 31 Comments
  • Why The Aspire Deal Is A Winner For Cellceutix Shareholders
    Dec. 18, 2012 CTIX 28 Comments
  • Watch Cellceutix Closely For Potential Catalysts In 2013
    Dec. 10, 2012 CTIX 20 Comments